Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Patented Breakthrough Technology Poised to Disrupt ECG Patch Market

HeartBeam (NASDAQ: BEAT) recently received a patent from the United States Patent and Trademark Office for its 12-lead electrocardiogram (“ECG”) patch monitor for the detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. “The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology. HeartBeam noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting… Currently, the ECG patch monitor market is limited to detecting arrhythmias using single-lead ECG devices. HeartBeam’s technology uses a synthesized 12-lead ECG that can aid physicians in both arrhythmia detection and ACS diagnosis, including myocardial infarction (heart attack) and angina. According to the company, the new patent follows HeartBeam’s already-granted core patents for remote detection of heart attacks,” a recent article reads. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability,” HeartBeam CEO and founder Branislav Vajdic, PhD, was quoted as saying.

To view the full article, visit

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in HeartBeam Inc. BEAT. Bookmark the permalink.

Comments are closed.